Aptevo Therapeutics receives $20 million payment from Emergent BioSolutions
Aptevo announced it has received a $20 million cash payment from Emergent BioSolutions pursuant to a promissory note granted as a result of the spin-off of Aptevo from Emergent. To date, Emergent has provided a total of $65 million in cash contributions to fund Aptevo’s operations. January 13, 2017